These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20019122)

  • 1. Relationship between epoetin alfa dose and mortality: findings from a marginal structural model.
    Wang O; Kilpatrick RD; Critchlow CW; Ling X; Bradbury BD; Gilbertson DT; Collins AJ; Rothman KJ; Acquavella JF
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):182-8. PubMed ID: 20019122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL.
    Bradbury BD; Danese MD; Gleeson M; Critchlow CW
    Clin J Am Soc Nephrol; 2009 Mar; 4(3):630-7. PubMed ID: 19261826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients.
    Kilpatrick RD; Critchlow CW; Fishbane S; Besarab A; Stehman-Breen C; Krishnan M; Bradbury BD
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1077-83. PubMed ID: 18417744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response.
    Gaweda AE; Goldsmith LJ; Brier ME; Aronoff GR
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):576-81. PubMed ID: 20110344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States.
    Zhang Y; Thamer M; Cotter D; Kaufman J; Hernán MA
    Clin J Am Soc Nephrol; 2009 Mar; 4(3):638-44. PubMed ID: 19261818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.
    Horowitz J; Agarwal A; Huang F; Gitlin M; Gandra SR; Cangialose CB
    J Manag Care Pharm; 2009; 15(9):741-50. PubMed ID: 19954265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia.
    Pergola PE; Gartenberg G; Fu M; Sun S; Wolfson M; Bowers P
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):598-606. PubMed ID: 20185602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL.
    Bradbury BD; Do TP; Winkelmayer WC; Critchlow CW; Brookhart MA
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):932-40. PubMed ID: 19572312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis.
    McGowan T; Vaccaro NM; Beaver JS; Massarella J; Wolfson M
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1006-14. PubMed ID: 18417741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring relative mortality and epoetin alfa dose among hemodialysis patients.
    Bradbury BD; Wang O; Critchlow CW; Rothman KJ; Heagerty P; Keen M; Acquavella JF
    Am J Kidney Dis; 2008 Jan; 51(1):62-70. PubMed ID: 18155534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients.
    Weinhandl ED; Gilbertson DT; Collins AJ
    Am J Nephrol; 2011; 34(4):298-308. PubMed ID: 21829009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease.
    Minutolo R; Chiodini P; Cianciaruso B; Pota A; Bellizzi V; Avino D; Mascia S; Laurino S; Bertino V; Conte G; De Nicola L
    Clin J Am Soc Nephrol; 2009 Mar; 4(3):552-9. PubMed ID: 19261821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia.
    Pergola PE; Gartenberg G; Fu M; Wolfson M; Rao S; Bowers P
    Clin J Am Soc Nephrol; 2009 Nov; 4(11):1731-40. PubMed ID: 19808215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.
    McClellan WM; Frankenfield DL; Wish JB; Rocco MV; Johnson CA; Owen WF;
    Am J Kidney Dis; 2001 May; 37(5):E36. PubMed ID: 11325701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease.
    Spinowitz B; Germain M; Benz R; Wolfson M; McGowan T; Tang KL; Kamin M;
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1015-21. PubMed ID: 18400964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients.
    Hahn D; Esezobor CI; Elserafy N; Webster AC; Hodson EM
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011690. PubMed ID: 28066881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
    Frankenfield DL; Johnson CA
    Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
    Nurko S; Spirko R; Law A; Dennis VW
    Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population.
    Sharma A; Yee J; Gandra SR; Khan I; Petersen J
    Curr Med Res Opin; 2010 Nov; 26(11):2679-87. PubMed ID: 20942616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.